marketbeat.com · 12 jun

argenx Eyes More VYVGART Growth as Pipeline Catalysts Near

Executives at argenex NASDAQ: ARGX told investors at a Goldman Sachs healthcare event that they continue to see meaningful growth opportunities for VYVGART across myasthenia gravis and chronic inflammatory demyelinating polyneuropathy, while also pointing to a busy slate of pipeline readouts in the second half of the year.

investors.com · 10 jun

Sanofi, An Argenx Rival, Bites The Dust — But A Third Biotech Took The Biggest Hit

Sanofi scrapped a final-phase study Wednesday of an experimental CIDP treatment. The stock tumbled in response.

zacks.com · 10 jun

ARGX Shares Gain Nearly 9% in a Month: Here's What You Need to Know

argenx stock rises nearly 9% in a month after the FDA expands Vyvgart's gMG label, opening treatment to adult patients regardless of antibody status.

seekingalpha.com · 10 jun

argenx SE (ARGX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

argenx SE (ARGX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

zacks.com · 8 jun

SRPT vs. ARGX: Which Stock Is the Better Value Option?

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Sarepta Therapeutics (SRPT) or argenex SE (ARGX). But which of these two companies is the best option for those looking for undervalued stocks?

zacks.com · 8 jun

Argenx (ARGX) Soars 5.8%: Is Further Upside Left in the Stock?

Argenx (ARGX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

marketbeat.com · 5 jun

argenx Touts VYVGART Growth, 50,000-Patient Goal at William Blair Conference

argenx NASDAQ: ARGX Chief Financial Officer Karl Gubitz told investors at the 46th Annual William Blair Growth Stock Conference that the biotechnology company remains focused on revenue growth, profitability and execution as it expands the VYVGART franchise and advances additional pipeline assets.

globenewswire.com · 3 jun

argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren's Disease at EULAR 2026

ALKIVIA+ data in myositis indicate efgartigimod provides sustained, clinically meaningful improvements and consistent safety RHO+ data in Sjogren's disease indicate maintenance of response following switch to biweekly dosing Cross-indication analysis of efgartigimod data across rheumatology studies underscores consistent safety profile in large patient population June 3, 2026, 7:00 AM CEST Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced the presentation of new data evaluating VYVGART® (IV: efgartigimod alfa-fcab and SC or Hytrulo: efgartigimod alfa and hyaluronidase-qvfc) across autoimmune rheumatic diseases, including myositis and Sjogren's disease, to be presented at the European Alliance of Associations for Rheumatology (EULAR) 2026 Congress from June 3-6, 2026, in London, UK. “Our presentations at EULAR further support the rationale for targeting FcRn in autoimmune rheumatic diseases and underscore its potential to address significant unmet patient need,” said Luc Truyen, M.D.